News | CellFree Sciences

header jp

header en


Our wheat germ cell-free expression system was used in a study to clarify the side effects of thalidomide.

Category: Announcements Created: Tuesday, 06 October 2020

Furihata, H., Yamanaka, S., Honda, T. et al. published in Nature Communications the results from a jointed project conducted by researchers at the University of Tokyo, Nagoya Institute of Technology, and our strategic partner the Proteo-Science Center at Ehime University using structural biology for determining the mechanisms behind side effects of immunomodulatory drugs like Thalidomide and its metabolite 5-hydroxythalidomide.


Thalidomide is used as an effective anti-cancer drug for treatment of multiple myeloma, although it exhibits side effects that cause developmental disorders in children during pregnancy. It is hoped that the results will help in the future to design better immunomodulatory drugs that mitigate the side effects.


This publication can be freely accessed: here.


We will be at BioJapan 2020.

Category: Society & Exhibition Created: Thursday, 01 October 2020



BJRM19 logos 06



CellFree Sciences will be at BioJapan 2020 at the PACIFICO Yokohama, Japan from October 14 to 16, 2020.

View in Google Map


Please visit us at the following booth locations.


◇Booth No. and Name: 

D-51/Cell Free Sciences with Ehime University (Protein Island Matsuyama)



Presentation Stage B

Date and time: October 14 15:00-15:30


We are looking forward to welcome you and to provide you with more information on the use of our protein expression products and services.


Reported in MED TECH Outlook.

Category: Articles Created: Friday, 28 August 2020

The international industry journal MED TECH Outlook reported on our company as a Top IN VITRO DIAGNOSTIC solution provider in APAC 2020.


For further details, Please click here.


The development serological markers for detecting recent Plasmodium vivax infection has been successful

Category: Press releases Created: Tuesday, 12 May 2020

The international research group comprising of Proteo-Science Center, Ehime University’s Dr. Eizo Takashima, Dr. Masayuki Morita, and Dr. Takafumi Tsuboi along with CellFree Sciences Co., Ltd.’s Dr. Matthias Harbers succeeded in developing a serological diagnostic marker that can identify those with dormant liver stage infections, which are the causes of Plasmodium v​​ivax recurrences.


This result has been achieved by an international joint research project with the main members including Proteo-Science Center, Ehime University, CellFree Sciences Co., Ltd., The Walter and Eliza Hall Institute of Medical Research (WEHI), Pasteur Institute, and Foundation for Innovative New Diagnostics (FIND).

Further, this project was started with assistance from the Global Health Innovative Technology Fund (GHIT Fund) between October 2015 and March 2017.


This research result allows the diagnosis of Plasmodium v​​ivax’s dormant liver stage parasites which has been a difficult challenge in eliminating malaria, for the first time in the world. It can be seen as an important result to safely and effectively promote the treatment.


The paper regarding this research result has been published on the May 12th (Tues.) 2020 issue of the Nature Medicine.

Development and validation of serological markers for detecting recent Plasmodium vivax infection


Additional comment


Contributed to support the development of monoclonal antibody detection of the novel coronavirus

Category: Announcements Created: Thursday, 23 April 2020


The joint research group, which primarily studies under Dr. Akihide Ryo for Yokohama City University, has succeeded in the development of monoclonal antibodies to specifically detect novel coronavirus (SARS-CoV-2) antigens, and has utilized our company's Wheat Germ Cell-free Protein Expression System in the production of the antigen.


For further details, Please click here.

Ehime University et al. receive research grant for development of malaria vaccines

Category: Announcements Created: Tuesday, 07 April 2020

The Proteo-Science Center (PROS), Ehime University et al. research group, which is the strategic technical partner of our company, has received a research grant totaling approximately 600 million yen for research to develop transmission-blocking vaccines for malaria elimination from Global Health Innovative Technology Fund (GHIT Fund).


Up to now we have supplied wheat germ extract to support malaria research through wheat germ cell-free protein expression system and it is our hope this malaria vaccine development will be one more step of progress in the battle to malaria elimination.

Contributed to novel coronavirus antibody detection technology

Category: Announcements Created: Friday, 20 March 2020

Our company's Wheat Germ Cell-free Protein Expression System was used to produce the antigen necessary for antibody detection in the technology developed by Dr. Akihide Ryo of Yokohama City University that is used to detect antiviral antibodies against novel coronavirus.


We in collaboration with Ehime University have developed a new technology to conduct a genome wide evaluation of the specificity of antibodies that can bind to human proteins.

Category: Press releases Created: Thursday, 19 December 2019

The groups from CellFree Sciences Co., Ltd. (Ryo Morishita, R&D manager)  and  Proteo-Science Center, Ehime University (Professor Tatsuya Sawasaki) have successfully developed a new technology that identifies proteins for binding to target antibodies. Using about 20,000 human proteins this technology is best suited for veriflying the specificity of antibodies against human proteins.


The new technology utilizes a protein bead array technology developed by CellFree Sciences Co., Ltd. named “CF-PA2Vtech”. The potential of the new method was demonstrated by verifying the specific binding of a commercial anti-PD-1 antibody, where the data demonstrate its binding to several proteins having related linear epitopes.


The results from the research were published by Morishita et al. in the December 18, 2019 issue of Scientific Reports:


CF-PA2Vtech: a cell-free human protein array technology for antibody validation against human proteins

We will be at The 10th Conference on Biomolecular Screenology.

Category: Society & Exhibition Created: Monday, 18 November 2019

CellFree Sciences will be at The 10th Conference on Biomolecular Screenology at Tower Hall Funabori, Tokyo, Japan from November 22, 2019.

View in Google Map


[Title of Abstract]
Antibody validation using a wheat germ cell-free based human protein array "CF-PA2Vtech".
[Poster No.]
November 22 (Fri.)
[Discussion Time]

We will be at The 48th Annual Meeting of the Japanese Society for Immunology.

Category: Society & Exhibition Created: Thursday, 14 November 2019






CellFree Sciences will be at the 48th Annual Meeting of the Japanese Society for Immunology at Act City Hamamatsu, Hamamatsu, Japan from December 11 to 13, 2019.

View in Google Map



[Title of Abstract]

Validation technology of antibody specificity using a protein array covering about 80% of the human proteome

[Poster No.]



December 11 (Wed.)

[Discussion Time]



We are looking forward to welcome you.


Copyright © CellFree Sciences Co.,Ltd. All Rights Reserved. [login]

We use cookies to ensure you get the best experience. By using our website you agree to our Cookie Policy.